Nigella sativa
Phase 2Small molecule
Nigella sativa is one of 12 small molecule programs targeting Atorvastatin. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Atorvastatin
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Crestor
AstraZenecaPhase 3
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Atorvastatin Calcium
Merck & Co.Phase 3
Lanoxin
AAdvanz Pharma
Phase 1
Novonorm
GGemini Therapeutics, Inc.
Phase 1
Glucophage
EMD SeronoPhase 1
Coumadin
AAbbott
Phase 1
RAY1225
GGuangdong Raynovent Biotech Co., Ltd
Phase 1
HDM1002
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertension1 trial
Oral1 trial
Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.
Completed·—·Phase 2·NCT03208790·48 enrolled
Atorvastatin1 trial
Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia
Recruiting·—·Phase 2·NCT06422650·84 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nigella sativa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IIndonesia University